133 related articles for article (PubMed ID: 35860981)
1. CD7 CAR T bridging to allo-HSCT in R/R T-ALL: A case report.
Fanqiao M; Chen X; Ren X; Li L; Wu T
Pediatr Transplant; 2024 May; 28(3):e14367. PubMed ID: 35860981
[TBL] [Abstract][Full Text] [Related]
2. Case report: Two pediatric cases of long-term leukemia-free survival with relapsed acute T-lymphoblastic leukemia treated with donor CD7 CAR-T cells bridging to haploidentical stem cell transplantation.
Song Y; Liu Z; Wang Q; Gao K; Wu T
Front Immunol; 2024; 15():1333037. PubMed ID: 38481998
[TBL] [Abstract][Full Text] [Related]
3. Donor CD7 Chimeric Antigen Receptor T Cell Bridging to Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Hematologic Malignancy.
Li Z; An N; Yang K; Meng F; Xu T; Peng X; Wen X; Li J; Song Y; Yang R; Wu T
Transplant Cell Ther; 2023 Mar; 29(3):167-173. PubMed ID: 36427783
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
5. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
6. Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report.
Li Z; Meng F; Li J; Wu T
Front Immunol; 2022; 13():931452. PubMed ID: 35903089
[TBL] [Abstract][Full Text] [Related]
7. [CAR T-cell bridging to allo-HSCT for relapsed/refractory B-cell acute lymphoblastic leukemia: the follow-up outcomes].
Yan M; Wu YJ; Chen F; Tang XW; Han Y; Qiu HY; Sun AN; Xue SL; Jin ZM; Wang Y; Miao M; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):710-715. PubMed ID: 33113601
[No Abstract] [Full Text] [Related]
8. CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report.
Wen S; Niu Z; Xing L; Wang Y; Li H; Kuang N; Luo J; Zhang X; Wang F
BMC Cancer; 2018 Nov; 18(1):1143. PubMed ID: 30458755
[TBL] [Abstract][Full Text] [Related]
9. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.
Cao XY; Zhang JP; Zhao YL; Xiong M; Zhou JR; Lu Y; Sun RJ; Wei ZJ; Liu DY; Zhang X; Yang JF; Lu P
Front Immunol; 2023; 14():1191382. PubMed ID: 37469510
[TBL] [Abstract][Full Text] [Related]
10. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
11. Demethylating agents in combination with CD7-targeted CAR-T for the successful treatment of a case with mixed-phenotype acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation: A Case Report.
Han Y; Yao H; He GC; Lai SH; Deng Y; Zhang S; He Y; Xiong YS; Chang AH; Su Y; Yi H
Front Immunol; 2023; 14():1254010. PubMed ID: 37841245
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
Cao XY; Li JJ; Lu PH; Liu KY
Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
[TBL] [Abstract][Full Text] [Related]
13. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
[No Abstract] [Full Text] [Related]
14. [Efficacy and safety of chimeric antigen receptor T-cell therapy followed by allogeneic hematopoietic stem cell transplantation in 21 patients with Ph-like acute lymphoblastic leukemia].
Dai HP; Shen HJ; Li Z; Cui W; Cui QY; Li MY; Chen SF; Zhu MQ; Wu DP; Tang XW
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):35-40. PubMed ID: 38527836
[No Abstract] [Full Text] [Related]
15. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
[TBL] [Abstract][Full Text] [Related]
16. Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.
Zhang C; Kong PY; Li S; Chen T; Ni X; Li Y; Wang M; Liu Y; Gao L; Gao L; Peng XG; Sun AH; Wang P; Yang Z; Zhang X; Qian C
J Immunother; 2018; 41(6):306-311. PubMed ID: 29864079
[TBL] [Abstract][Full Text] [Related]
17. Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation.
Jiang Y; Feng D; Zhu J; Wei D; Zhao C; Liu H; Shao S; Wang C
Front Immunol; 2024; 15():1381308. PubMed ID: 38745670
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ
Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.
Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386
[TBL] [Abstract][Full Text] [Related]
20. Multiple CAR-T cell therapy for acute B-cell lymphoblastic leukemia after hematopoietic stem cell transplantation: A case report.
Deng L; Xiaolin Y; Wu Q; Song X; Li W; Hou Y; Liu Y; Wang J; Tian J; Zuo X; Zhou F
Front Immunol; 2022; 13():1039929. PubMed ID: 36466893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
